AAIC 2025 Abstract
Pharmacological characterization of DA‐7503: a novel tau aggregation inhibitor in clinical development for Alzheimer’s disease and primary tauopathies
Experiments in animalsInterventions
Abstract
Background: DA‐7503 is a potential first‐in‐class, orally available small‐molecule inhibitor of tau oligomerization, currently in clinical development for the treatment of Alzheimer’s disease and primary tauopathies.
